Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Fostamatinib Disodium in Warm Antibody Autoimmune Hemolytic Anemia
2018-004774-97Phase 3Unknown
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) comparing Fostamatinib with Placebo (2 arms). Primary endpoint: Durable response. Status: unknown.
02
Drugs
fostamatinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2018-004774-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004774-97.